代谢功能障碍相关脂肪性肝炎（MASH/NASH）的 发病机制、治疗靶点与药物开发
代谢功能障碍相关脂肪性肝炎由肝脂肪沉积、脂毒性、胰岛素抵抗、炎症和纤维化共同驱动。靶向脂质代谢、核受体、肠促胰素及FGF信号已成为药物开发的主要方向。
主题
NASH
以下是知识库中与该主题相关的实验方案、常见问题、指南与技术文章。
4 项资源 · 实验方案、常见问题与文章
Pathogenesis, Therapeutic Targets, and Drug Development for Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH)
Metabolic dysfunction-associated steatohepatitis is jointly driven by hepatic fat accumulation, lipotoxicity, insulin resistance, inflammation, and fibrosis. Targeting lipid metabolism, nuclear receptors, incretin pathways, and FGF signaling has become a major direction in drug development.
Construction and Evaluation of Hepatic Fibrosis Animal Models: Toxic Injury, Cholestasis, Immune Inflammation, and Metabolism-Related Models
Hepatic fibrosis (HF) is a pathological process characterized by excessive deposition and abnormal remodeling of extracellular matrix (ECM) after chronic liver injury. Repeated hepatocyte injury, inflammatory infiltration, cholestasis, lipotoxicity, or immune responses can activate hepatic ...
肝纤维化动物模型构建与评价：毒性损伤、胆汁淤积、免疫炎症和代谢相关模型
肝纤维化（hepatic fibrosis, HF）是慢性肝损伤后细胞外基质（extracellular matrix, ...
相关主题
同一批资源中共同出现的其他主题。
危险品化学品经营许可证（带存储）